Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Mark McPartland - SVP, IR Shawn Singh - CEO Cindy Anderson - CFO Josh Prince - COO Conference Call Participants Julian Pino - Stifel Andrew Tsai - Jefferies Myles Minter - William Blair Madison El-Saadi - B. Riley Securities Operator Good afternoon, ladies and gentlemen, and welcome to the Vistagen Therapeutics Fiscal Year 2025 Second Quarter Corporate Update Conference Call. [Operator ...

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -5%. A quarter ago, it was expected that this company would post a loss of $0.41 per share when it actually produced a loss of $0.35, delivering a surprise of 14.63%. Over the last four quarters, the company h ...

Exhibit 99.1 Vistagen Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing PALISADE-3 and PALISADE-4 Phase 3 trials initiated and underway SOUTH SAN FRANCISCO, Calif. — (BUSINESS WIRE) — November 7, 2024 — Vistagen(Nasdaq: VTGN), a late clinicalstage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported finan ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share VTGN Nasdaq Capital Market Large accelerated filer o Accelerated filer o Non-Accelerated filer x Smaller reporting company x Emerging growth company o UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September ...

Vistagen (NASDAQ: VTGN ) is continuing on with phase 3 development of its nasal spray containing fasedienol for social anxiety disorder. I haven't looked at VTGN since April, when I considered the name a hold, as the Scientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice. Analyst's Disclosure: I/we have no stock, ...

VistaGen Therapeutics, Inc. (VTGN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. The pow ...

VistaGen Therapeutics, Inc. (VTGN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by ...

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2025 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Mark McPartland - SVP, IR Shawn Singh - CEO Cindy Anderson - CFO Josh Prince - COO Conference Call Participants Andrew Tsai - Jefferies Tim Lugo - William Blair Madison Elsaadi - B. Riley Securities Operator Ladies and gentlemen, greetings and welcome to Vistagen Therapeutics Fiscal Year 2025 First Quarter Corporate Update Conference Call. At this time, all participants are in a listen- ...

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.94 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 14.63%. A quarter ago, it was expected that this company would post a loss of $0.34 per share when it actually produced a loss of $0.25, delivering a surprise of 26.47%. Over the last four quarters, the compan ...

Exhibit 99.1 Vistagen Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update PALISADE Phase 3 Program for the acute treatment of Social Anxiety Disorder progressing on track SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)—August 13, 2024-- Vistagen(Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neuro ...